2016-06-01 19:21:38 UTC

Sofosbuvir Plus Ribavirin Shows Promise in Complicated HCV Genotype 2 Patients

June 1, 2016

Phase 4 study results published in CGH find that this treatment combo is effective in almost 80 percent of HCV genotype 2 patients with cirrhosis.

A new Clinical Gastroenterology and Hepatology (CGH) article in press highlights the results of a Phase 4, open-label study to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus (HCV) genotype 2 infection and compensated cirrhosis.

The research team, led by Samuel B. Ho, MD, conclude that 12-weeks treatment with sofosbuvir and ribavirin led to a sustained virologic response (SVR) in almost 80 percent of veterans with HCV genotype 2 infection, compensated cirrhosis and multiple comorbidities, regardless of their treatment history.

The presence of depression, post-traumatic stress disorder or substance use did not impact the treatment outcome in this study, indicating that patients with these coexisting conditions can expect to achieve SVR rates similar to those without them.

This study represents the largest group of HCV genotype 2 patients with cirrhosis studied in a prospective trial of sofosbuvir and ribavirin to date. Review the full study on the CGH website (login required).

More on Cirrhosis

How to Achieve High-Value Care in GI and Hepatology

Jan. 3, 2018

A new AGA article series in CGH provides guidance to help you efficiently manage your practice.

New to CGH! Audio Summaries

Jan. 3, 2018

In the first audio summary, Clinical Gastroenterology and Hepatology editor in chief Dr. Fasiha Kanwal summarizes January’s top articles.

Digestive Disease Week® (DDW)

Dec. 19, 2017

Digestive Disease Week® (DDW) is the premier meeting for the GI professional. Every year it attracts approximately 15,000 physicians, researchers and academics from around the world who desire to stay up-to-date in the field.